News & Updates

Adults who contract respiratory syncytial virus (RSV) infection appear to be at increased risk of cardiovascular events, according to a study.

The oral PCSK9 inhibitor enlicitide lowers LDL-cholesterol (LDL-C) levels and other atherogenic lipids in high-risk patients with hypercholesterolaemia, as shown in the CORALreef Lipids study presented at AHA 2025.

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) secondary to Chagas disease, the use of sacubitril/valsartan does not appear to lead to improvements in clinical outcomes compared with enalapril, according to a study.

A sedentary behaviour appears to contribute to increased arterial stiffness among older adults, suggests a recent study.

A recent study has shown the association of greater arterial stiffening with both ocular (small) and peripheral (large) fiber neuropathies.

Individuals with a family history of hypertension show increased central and peripheral blood pressure (BP) potentially due to higher systemic vascular resistance (SVR), according to a study. On the other hand, large artery stiffness is not elevated.

Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.

A study presented at IDWeek 2025 demonstrates substantial medication cost savings, shorter hospital stays, reduced treatment duration, and lower rates of progression to severe disease when nirmatrelvir-ritonavir (NMV/r) was added to the acute care formulary for treating elderly patients with mild-to-moderate COVID-19.

The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.